MJ-33 is a competitive phospholipase A2 (PLA2) inhibitor. MJ-33 inhibits the activation of NOX2 by blocking the PLA2 activity of Prdx6, thereby reducing the production of ROS. MJ-33 effectively inhibits the activity of acidic PLA2 (pH 4.0), reduces the degradation of pulmonary surfactant phosphatidylcholine (PC), but has no effect on alkaline PLA2 (pH 8.5). MJ-33 significantly alleviates lung oxidative damage induced by ischemia-reperfusion (I/R). MJ-33 significantly inhibits the invasive, migratory and adhesive abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-kappaB and AP-1 signaling pathways. MJ-33 can be used to study ROS-related diseases and prostate cancer[1][2][3].
Molekulargewicht:
492.55
CAS Nummer:
[137300-78-8]
Formel:
C22H44F3O6P
Target-Kategorie:
Akt,AP-1,NADPH Oxidase,NF-kappaB,p38 MAPK,Phospholipase,Reactive Oxygen Species (ROS)
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
